Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA
Funding The preparation of this review was not supported by any external funding.
Authorship and conflict of interest Z. T. Al-Salama is a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives. She was not involved in any publishing decisions for the manuscript and declares no declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here
Amantadine extended release (ER) [GOCOVRI®], an NMDA receptor antagonist, is an important treatment option in the management of levodopa-induced dyskinesia (LID) and OFF episodes in patients with Parkinson’s disease (PD). Taken at bedtime, amantadine ER provides low plasma levels overnight and high plasma concentrations during the waking day (i.e. delayed release). In randomised, double-blind, placebo-controlled phase III trials in adults with PD, once-daily amantadine ER was effective in improving LID, reducing OFF time and increasing ON time without troublesome dyskinesia, compared with placebo. Control of motor complications with amantadine ER was evident throughout the day, with fewer transitions between motor states. The clinical benefits of amantadine ER in reducing the duration and impact of dyskinesia and OFF episodes were durable with long-term treatment. Amantadine ER is generally well tolerated, including in the long term, with the majority of adverse events being mild or moderate in severity.
© Springer Nature Switzerland AG 2022